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1 Introduction
We should, perhaps, consider migraine as a two-stage
disorder. Stage 1 is the underlying biochemical disorder
(migraine disorder) that predisposes the sufferer to stage 2,
which is the manifestation of the disorder as a migraine
headache.
The triggers of migraine headaches are multifarious.
Some sufferers of migraine disorder link their migraine
attacks to eating specific foods (e.g. chocolate, cheese),
specific situations (e.g. stress), the time of year or even
weather conditions [1].
Treatments for migraine are equally diverse and might
be based on what are thought by the physician to be the
underlying causes of the migraine attack (e.g. use of
b-blockers to reduce local brain blood pressure) or use of
drugs designed to treat the migraine headache per se (e.g.
triptans).
2 What is the Underlying Biochemistry of Migraine?
There is no definitive answer to the question of what
underlies migraine disorder or triggers migraine headaches.
Current thinking points to migraine being a brain disorder
related (at least in part) to serotonin [5-hydroxytryptamine
(5-HT)] and/or dopamine (DA) and their receptors, and
no single, simple, mechanism is thought to account for the
disease [2]. When the actions elicited by DA are
considered—including mind, mood and behaviour
effects—the complexity of the disease is understandable.
The concentrations of 5-HT and DA in the synapse are
important in determining their effects; for this reason, there
are several synaptic concentration control mechanisms and
several postsynaptic receptors that elicit different effects.
The control mechanisms involve presynaptic 5-HT or DA
receptors, which, when occupied, cause a series of cyclic
adenosine monophosphate (cAMP)-mediated events that
result in reduced release of either DA or 5-HT from
presynaptic vesicles into the synapse. In addition, there are
presynaptic membrane transporters for either DA (i.e.
DAT) or 5-HT that pump the neurotransmitter from the
synapse back into the presynaptic nerve terminal, where it
is, in turn, pumped into presynaptic vesicles for reuse later.
A combination of the DA or 5-HT transporters and the
presynaptic feedback receptors together allow fine control
of synaptic neurotransmitter concentrations (Fig. 1).
Both DA and 5-HT work by binding to postsynaptic
receptors, resulting in initiation of a wave of depolarization
(action potential), which elicits the response. In addition,
similar receptors are found on muscles at neuromuscular
synaptic junctions. Such junctions might exist between, for
example, serotonergic nerves and blood vessel walls, re-
sulting in vessel contraction and increased blood pressure.
This might explain the link between migraine headaches,
DA/5-HT and localized brain blood pressure changes [2].
Presynaptic inhibitory receptors are key facets of the
control of neurotransmitter synthesis. Clearly, the relative
binding constants for specific neurotransmitters (e.g. DA) to
specific receptors determine the overall effect of a particular
neurotransmitter concentration in the synapse. Therefore,
the concentration of a particular neurotransmitter (or the
ratio of concentrations between several neurotransmitters)
in the synapse determines the overall effect.
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Further to this, there is a plethora of receptor subtypes
that have specific effects and binding constants for one or
more neurotransmitters. For example, 5-HT1B is a subtype
of the 5-HT receptor family; 5-HT has various affinities for
receptor subtypes, as do 5-HT mimics such as triptans
(used to treat migraine headaches). In addition, there is a
class of central nervous system (CNS) trace amine recep-
tors (TAARs) that appear to be distinct from classical
biogenic amine (e.g. 5-HT) receptors. TAARS bind tyra-
mine, b-phenylethylamine, tryptamine and octopamine,
which are present at trace levels in the mammalian CNS
[3].
Trace amines (e.g. tyramine) have been implicated in
the aetiology of migraine. Indeed, consumption of foods
rich in tyramine (e.g. cheese) are often linked to headaches
by migraine sufferers. Tyramine might be present in foods
per se, it might be produced from tyrosine-rich foods by
gut microfloral decarboxylation or it might be produced in
the CNS from tyrosine. Tyramine is structurally analogous
to 5-HT, and therefore it is possible that it interacts with
5-HT receptors or transporters, which might explain its link
with headaches in some migraine sufferers. Interestingly, a
clinical study carried out in the 1970s showed that
administration of tyramine to migraine sufferers did not
precipitate headaches [4]. This study focused on tyramine
in isolation; however, it is possible that if tyramine has a
role in migraine, it is more complex, and that dietary
tyramine is only one component of a complex array of risk
factors necessary to precipitate a headache. Many migraine
sufferers still tell their doctors that their headaches are
precipitated by tyramine-containing foods—even if Moffet
and her colleagues argue otherwise [4].
From this brief discussion, it is clear that migraine dis-
order and/or migraine headache, their triggers and treat-
ments are inextricably linked through possible interactions
of 5-HT molecular mimics with postsynaptic receptors,
presynaptic inhibitory receptors and/or transporters. The
potential complexity of these interactions is overwhelming.
Migraine triggers might mimic neurotransmitters, lead-
ing to neurotransmitter synaptic concentration irregularities
with consequent unscheduled nerve firing. This might
explain phantom sensory effects, such as the flashing lights
described by many migraine sufferers.
The functionality of this complex receptor/transporter-
based control/effect system relies upon the differential
binding affinities of the different receptors and transporters.
These differential binding affinities ensure that the synaptic
neurotransmitter concentrations determine occupancy of
the postsynaptic receptors (and therefore the effect) and that
above a particular concentration, binding to the presynaptic
receptor occurs (thus inhibiting neurotransmitter synthesis)
and/or that binding to the transporter occurs (thus reducing
synaptic neurotransmitter concentration).
We have focused on DA and 5-HT thus far; however,
other neurotransmitters operate by similar systems (e.g.
noradrenaline) and have also been implicated in the aeti-
ology of migraine [5]. This adds further to the complexity
of this receptor-mediated disease.
It is clear that if a molecule or a stimulus that releases a
molecule that interferes with any aspect of this system
occurs that profound neurological effects might result. For
example, tyramine present in chocolate, cheese and soy
sauce has structural analogies with DA (and noradrenaline)
[Fig. 2] and so could interact with the dopaminergic system
by binding to DA receptors or DAT, which might explain
its link to migraine in some people [4].
Interestingly, migraine disorder is more common in












Fig. 1 Schematic representation of 5-hydroxytryptamine/dopamine










Fig. 2 a Tyramine. b Noradrenaline. c Dopamine
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pregnant migraine sufferers in the third trimester [7],
transdermal estrogens can be used in prophylactic treat-
ment, and it is rare in postmenopausal women. Clearly,
estrogen(s) is/are likely involved in the disorder. Interest-
ingly, 17b-estradiol (E2) modulates 5-HT1 receptors in the
rat brain [8], which suggests a link between E2 levels and
5-HT-mediated effects.
3 Treatment of Migraine
Treatment can be classified as either acute or preventative
[9–11]; acute treatment is further divided into migraine-
specific or non-specific treatment [11]. The former osten-
sibly impacts on the cellular mechanisms of the disease
(e.g. local cerebral blood pressure changes), while the latter
focuses on underlying migraine triggers (e.g. anxiety).
Specific migraine treatments include ergotamine, dihy-
droergotamine (DHE) and triptans (e.g. rizatriptan). These
drugs are all agonists of 5-HT receptors; ergotamine is a
5-HT1B receptor agonist, DHE is a 5-HT1 receptor agonist
[12] and the triptans are 5-HT1B/1D agonists [11]. Such
drugs rapidly ameliorate the migraine headache, presum-
ably by addressing anomalies in synaptic 5-HT
concentrations.
There are many preventative drugs given to reduce the
frequency and severity of anticipated migraines [13]; their
effects and efficacies are variable [10]. These treatments
can be classified according to their primary therapeutic
uses, including b-blockers (e.g. propranolol), antidepres-
sants (e.g. amitriptyline), calcium channel antagonists (e.g.
verapamil), anticonvulsants (e.g. valproic acid) and 5-HT
receptor antagonists (e.g. pizotifen) [14].
It is interesting that despite the preventative drugs
having very different primary therapeutic uses, they (or
their metabolites) have molecular similarities and sig-
nificant structural analogies with DA or 5-HT (Fig. 3);
therefore, it is possible that these drugs, despite the
therapeutic rationale underlying their efficacy in migraine
treatment, work via mechanisms related to DA and/or 5-HT
receptor or transporter systems, which might not be their
primary modes of action. On the other hand, the primary
modes of action of some of these drugs might indeed be via
DA or 5-HT receptor interactions, but the desired outcome
was to treat other DA/5-HT-related disorders (e.g.
depression) for which the drugs were originally ‘designed’,
rather than treating migraine. In these cases, the drugs’
usefulness in migraine treatment is fortuitous.
The structural analogies shown in Fig. 3 are based on
either major metabolite or parent molecule structural
similarities with neurotransmitters. A closer look at the
metabolic pathways of amitriptyline and verapamil reveals
other metabolites with closer structural analogies to the
neurotransmitters. For example, verapamil is metabolized
by cleavage of the C–N bond in the aliphatic chain that
links its two aromatic centres (see Fig. 3) to form a
metabolite (M6) [15], which has a significant three-
dimensional structural analogy to DA (Fig. 4).
Interestingly, mood and feeling of wellbeing are af-
fected by DA and or 5-HT [16], which likely explains the
modes of action of tricyclic antidepressants [17] (e.g.
amitriptyline and imipramine) and, in turn, might explain
why these drugs are also useful in the treatment of
migraine. Indeed, pizotifen, a drug primarily used for
migraine treatment, has structural analogies with 5-HT and
is a 5-HT antagonist [18].
A closer look at the molecular similarities between
drugs used to treat migraine, their molecular analogies with
DA or 5-HT and their possible interactions with, for
example, 5-HT receptors might give an insight into the
molecular structures for new antimigraine drugs. It might
even be possible to specify molecular dimensions in terms
of separation and orientation of key molecular moieties

























Fig. 3 Molecular structures of a the hydroxy-metabolite of the
b-blocker propranolol [black], showing its structural analogy to
dopamine (DA) [grey]; b the hydroxy-metabolite of the antidepressant
amitriptyline [black], showing its structural analogy to 5-hydrox-
ytryptamine (5-HT) [grey]; and c the antianginal antiarrhythmic
verapamil [black], showing its structural analogy to DA [grey]
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transporters. For example, importing 5-HT into the binding
cleft of 5-HT receptor derived from a 5-HT1B-BRIL/er-
gotamine crystal structure [19], using ChemBio 3D Ultra
(Perkin Elmer), shows the best fit orientation of the
ligand and the theoretical positions of hydrogen bonds with
amino acid residues in the binding cleft (Fig. 5). The
5-HT1B-BRIL/ergotamine crystal structure is used for this
example because there is no crystal structure published for
a 5-HT receptor with 5-HT in the binding cleft. Ergotamine
has been removed and 5-HT fitted so that it bonds to the
same key amino acid residues as the agonist.
Hydroxyamitriptyline (OH-AT), a metabolite of
amitriptyline, has a significant three-dimensional molecular
structural analogy to 5-HT (Fig. 6). When OH-AT is su-
perimposed onto 5-HT in ChemBio 3D, their side chain
nitrogens are only 1.1 A˚ apart and their ring hydroxyls are
only 1.3 A˚ apart. This suggests that OH-AT would fit and
hydrogen bond to 5-HT1B. In terms of molecular moiety
separation, the ring hydroxyl and the side chain (or
equivalent) nitrogen should be of the order of 5.6 A˚
separated to fit and hydrogen bond to 5-HT1B. This is a
simple example that illustrates the importance of three-
dimensional molecular dimensions and natural ligand
mimicry in determining likely receptor fit and consequent
potential pharmacological activity.
Therefore, it is likely that drugs used for the treatment of
migraine were originally used because they were thought to
treat the underlying cause of a particular patient’s
migraine. However, on further scrutiny, it is perhaps more
likely that, fortuitously, these drugs have effects that also




(DA) [left] and the verapamil
metabolite M6 [right], seen
from different orientations
[above and below]. The
molecular analogies are clear in
a three-dimensional context,
which supports the possibility
that M6 could interact with the
dopamine transporter at the DA
binding site
Fig. 5 5-Hydroxytryptamine
(5-HT) imported in silico into a
5-HT1B-BRIL/ergotamine
crystal structure [19] following
removal of ergotamine, using
ChemBio 3D Ultra, showing the
hydrogen bonds (and their bond
lengths), likely formed with key
amino acid residues in the
binding cleft
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This thinking not only supports the increasing evidence
that migraine is a brain disorder involving the 5-HT and/or
DA systems, but also provides a rationale for migraine drug
design.
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